


Application No.: 09/820,420

Docket No.: 55507US016

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)
2. (Currently Amended) ~~The method of Claim 1~~ A method of treating dermal lesions caused by venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound to the site of the lesion, wherein the immune response modifier compound is a compound of Formula I



wherein

R<sub>1</sub> is selected from the group consisting of S and NR<sub>3</sub>,

R<sub>2</sub> is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and


R<sub>3</sub> is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.

3. (Original) The method of Claim 2 wherein R<sub>1</sub> is NR<sub>3</sub>.
4. (Original) The method of Claim 2 wherein R<sub>1</sub> is S.
5. (Original) The method of Claim 2 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.

Application No.: 09/820,420

Docket No.: 55507US016

6. (Original) The method of Claim 2 wherein  $R_3$  is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.
7. (Original) The method of Claim 2 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl- $\alpha,\alpha$ -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*HI*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.
8. (Currently Amended) The method of Claim 1 wherein the immune response modifier compound is applied via a cream or a gel.
9. (Currently amended) The method of claim 1 wherein the site of the lesion comprises a spider bite.
- 10-14. (Canceled)
15. (Currently Amended) ~~The method of Claim 14~~ A method of inhibiting dermonecrosis caused by venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound to the site of the venom-induced immune dysregulation, wherein the immune response modifier compound is a compound of Formula 1



1

wherein

 $R_1$  is selected from the group consisting of S and  $NR_3$ , $R_2$  is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy

Application No.: 09/820,420

Docket No.: 55507US016

moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and

R<sub>3</sub> is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.

16. (Original) The method of Claim 15 wherein R<sub>1</sub> is NR<sub>3</sub>.
17. (Original) The method of Claim 15 wherein R<sub>1</sub> is S.
18. (Original) The method of Claim 15 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.
19. (Original) The method of Claim 15 wherein R<sub>3</sub> is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.
20. (Original) The method of Claim 15 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl- $\alpha,\alpha$ -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.
21. (Currently amended) The method of Claim ~~44~~ 15 wherein the immune response modifier compound is applied via a cream or a gel.
22. (Currently amended) The method of claim ~~44~~ 15 wherein the site of the venom-induced immune dysregulation comprises a spider bite.
- 23-26. (Canceled)